In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Angiotech Pharmaceuticals, Inc.

http://www.angiotech.com

Latest From Angiotech Pharmaceuticals, Inc.

Lupin And Zentiva Snatch First Generic Raltegravir Approval In UK

The UK’s MHRA has approved the first generic raltegravir to treat HIV in adults and certain pediatric patients and deemed the drug interchangeable with the originator Isentress.

Generic Drugs Launches

Digital Health Roundup: Brain Talk On Seizures, Alzheimer's, Stress, Anxiety; Medtronic's OR Report; Health Care AI; UK Guidances

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights AI discussions at the HLTH Europe conference and an interview with Motif Neurotech's CEO Jacob Robinson. Elizabeth Orr discusses DeepWell DTx's newly launched VR game for treating stress-related hypertension and anxiety. Natasha Barrow provides an overview of Digital Mental Health Technologies regulation in the UK and Brian Bossetta reports ‘the good and bad’ from Medtronic's report on digital technologies' use in the operating room. 

Digital Health Roundup Digital Health

Endo En Route To NYSE With Common Stock Exchange Expected Later In 2024

Endo continues to stride its financial revival path, with the latest plans to list common stock on the NYSE. Also, the firm has just launched a generic tiopronin rival to Travere Therapeutics' Thiola.

Financing Strategy

Agenus Needs Phase III For BOT/BAL, Another Example Of Shifting Accelerated Approval Climate

The US FDA surprised some observers when it advised Agenus against filing for accelerated approval of the CTLA-4/PD-1 combination, but the agency has been cracking down on confirmatory trial requirements recently to better ensure the studies will be finished.

Cancer Review Pathway
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
    • Consumables, Central Supplies
    • Implantable Devices
    • Infection Control-Sterilization
    • Infusion Therapy Equipment and Supplies
    • Laser
    • Monitoring Equipment & Devices
    • Radiofrequency Devices
    • Rehabilitation Equipment and Devices
    • Surgical Equipment & Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Other Names / Subsidiaries
    • Quill Medical Inc.
    • Surgical Specialties Corporation, Inc.
UsernamePublicRestriction

Register